Journal ArticleDOI
Bioactive natural products from the genus Salinospora: a review
Reads0
Chats0
TLDR
This review arranged Salinispora derived secondary metabolites according to the three species that comprise the genus and described muta- and semi-synthesis analogs derived from salinosporamide.Abstract:
Actinomycetes are an important source for bioactive secondary metabolites. Among them, the genus Salinispora is one of the first salt obligatory marine species worldwide and is typically found in various types of substrates in tropical and subtropical marine environments including sediments and marine organisms. This genus produces a wide range of chemical scaffolds and bioactive compounds such as lomaiviticins, cyclomarins, rifamycins, salinaphthoquinones, and salinosporamides. This review arranged Salinispora derived secondary metabolites according to the three species that comprise the genus. Moreover, muta- and semi-synthesis analogs derived from salinosporamide were also described in this review.read more
Citations
More filters
Journal Article
Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica
Daniel W. Udwary,Lisa Zeigler,Ratnakar N. Asolkar,Vasanth R. Singan,Alla Lapidus,William Fenical,Paul R. Jensen,Bradley S. Moore +7 more
TL;DR: This study firmly establishes the genus Salinispora as a rich source of drug-like molecules and importantly reveals the powerful interplay between genomic analysis and traditional natural product isolation studies.
Journal ArticleDOI
Integrating perspectives in actinomycete research: an ActinoBase review of 2020-21.
Agustina Undabarrena,Camila Cristina Galvão Francisco Pereira,Worarat Kruasuwan,Jonathan Parra,Nelly Selem-Mojica,Kristiina Vind,Jana K. Schniete +6 more
TL;DR: The second ActinoBase review as discussed by the authors highlighted the research of particular interest to the actinomycete community, focusing on research using integrative methodologies and approaches to understand the bigger picture of actinomecete biology, covering four research areas: technology and methodology; specialised metabolites; development and regulation; ecology and host interactions.
Journal ArticleDOI
Genetic and Physiological Diversity of Marine Actinobacteria from the Okha Coast, Gujarat, India
TL;DR: In this paper , the authors explored Saline and alkaline habitats of the Okha coastline, Gujarat, India, were explored for the diversity of actinobacteria based on the phenotypic and genotypic heterogeneity.
Journal ArticleDOI
A Metabolomics-Based Toolbox to Assess and Compare the Metabolic Potential of Unexplored, Difficult-to-Grow Bacteria
Federica Fiorini,Felizitas Bajerski,Olga Jeske,Cendrella Lepleux,Jörg Overmann,Mark Brönstrup +5 more
TL;DR: In this article , a workflow to identify promising producers of novel natural products by systematically characterizing their metabolomes is presented, where 60 strains from four phyla (Proteobacteria, Bacteroidetes, Actinobacteria and Firmicutes) comprising 16 novel species and six novel genera were cultivated from marine and terrestrial sources.
Journal ArticleDOI
Influence of Cultivation Conditions on the Sioxanthin Content and Antioxidative Protection Effect of a Crude Extract from the Vegetative Mycelium of Salinispora tropica
TL;DR: In this paper, the effect of cultivation temperature (T) and light intensity (LI) on the total cellular carotenoid content (TC), antioxidant activity (AA), and sioxanthin content (SX) of a crude extract (CE) from Salinispora tropica biomass in its vegetative state was evaluated.
References
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
Alfred W. Alberts,Julie S. Chen,G Kuron,V Hunt,Jesse W. Huff,Carl H. Hoffman,John W. Rothrock,Lopez Maria B,Henry Joshua,Elbert E. Harris,Arthur A. Patchett,R L Monaghan,S Currie,E Stapley,George Albers-Schonberg,Otto D. Hensens,J Hirshfield,Karst Hoogsteen,Jerrold M. Liesch,James P. Springer +19 more
TL;DR: It was shown that mevinolin was an orally active cholesterol-lowering agent in the dog and orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay.
Journal ArticleDOI
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.
Feling Robert H R,Greg O. Buchanan,Tracy J. Mincer,Christopher A. Kauffman,Paul R. Jensen,William Fenical +5 more
TL;DR: The ocean is an overlooked habitat from which to isolate important microorganisms, and the rate of discovery of new biologically active compounds from common soil actino-mycetes has been falling.
Journal ArticleDOI
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,D. Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +14 more
TL;DR: Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.
Journal ArticleDOI
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Dharminder Chauhan,Laurence Catley,Guilan Li,Klaus Podar,Teru Hideshima,Mugdha Velankar,Constantine S. Mitsiades,N. Mitsiades,Hiroshi Yasui,Anthony Letai,Huib Ovaa,Celia R. Berkers,Benjamin Nicholson,Ta-Hsiang Chao,Saskia T. C. Neuteboom,Paul G. Richardson,Michael A. Palladino,Kenneth C. Anderson +17 more
TL;DR: It is shown that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and Bortezomib therapies, which provides the rationale for clinical protocols evaluating NPI -0052, alone and together with Bortzomib, to improve patient outcome in MM.
Related Papers (5)
Marine rare actinomycetes: A promising source of structurally diverse and unique novel natural products
Ramesh Subramani,Detmer Sipkema +1 more